Cogent Biosciences (COGT) Preferred Stock Liabilities (2017 - 2021)
Cogent Biosciences (COGT) posted quarterly Preferred Stock Liabilities of $85.4 million for Q3 2021, down 38.22% year-over-year from $138.2 million in Q3 2020, and little changed quarter-over-quarter from $85.4 million in Q2 2021.
Cogent Biosciences (COGT) Preferred Stock Liabilities (2017 - 2021) Analysis & Trends
Cogent Biosciences (COGT) has reported Preferred Stock Liabilities for 4 consecutive years, with $85.4 million the latest figure, recorded in Q3 2021.
- In Q3 2021, Preferred Stock Liabilities fell 38.22% year-over-year to $85.4 million; the TTM figure through Sep 2021 stood at $85.4 million (down 38.22% YoY), while the FY2020 annual figure was $110.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $85.4 million in Q3 2021 per COGT's latest filing, from $85.4 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $138.2 million in Q3 2020 and bottomed at $77.2 million in Q4 2017.
- Historically, Preferred Stock Liabilities has averaged $95.6 million across 4 years, with a median of $85.4 million in 2021.
- On a YoY basis, Preferred Stock Liabilities climbed as much as 38.22% in 2021 and fell as far as 38.22% in 2021.
- Cogent Biosciences' Preferred Stock Liabilities stood at $77.2 million in 2017, then climbed by 0.02% to $77.2 million in 2018, then surged by 43.69% to $110.9 million in 2020, then fell by 22.98% to $85.4 million in 2021.
- Business Quant data shows COGT's Preferred Stock Liabilities at $85.4 million in Q3 2021, $85.4 million in Q2 2021, and $94.7 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 85.40 Mn |
| Jun 30, 2021 | 85.40 Mn |
| Mar 31, 2021 | 94.68 Mn |
| Dec 31, 2020 | 110.88 Mn |
| Sep 30, 2020 | 138.23 Mn |
| Mar 31, 2018 | 77.17 Mn |
| Dec 31, 2017 | 77.15 Mn |